Inarigivir soproxil
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Inarigivir soproxil
- DrugBank Accession Number
- DB15063
- Background
Inarigivir soproxil is under investigation in clinical trial NCT03434353 (Study to Evaluate the Antiviral Activity of Inarigivir (GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 703.62
Monoisotopic: 703.167292355 - Chemical Formula
- C25H34N7O13PS
- Synonyms
- Inarigivir soproxil
- External IDs
- SB 9200
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 365052M0DK
- CAS number
- 942123-43-5
- InChI Key
- CJCYTUJOSMYXLE-JDLSZIHUSA-N
- InChI
- InChI=1S/C25H34N7O13PS/c1-12(2)42-25(37)40-11-47-46(38,45-19-14(7-33)44-23(20(19)39-3)31-5-4-16(35)30-24(31)36)41-8-15-13(34)6-17(43-15)32-10-29-18-21(26)27-9-28-22(18)32/h4-5,9-10,12-15,17,19-20,23,33-34H,6-8,11H2,1-3H3,(H2,26,27,28)(H,30,35,36)/t13-,14+,15+,17+,19+,20+,23+,46?/m0/s1
- IUPAC Name
- 1-[(2R,3R,4R,5R)-4-[({[(2R,3S,5R)-5-(6-amino-9H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy}[({[(propan-2-yloxy)carbonyl]oxy}methyl)sulfanyl]phosphoryl)oxy]-5-(hydroxymethyl)-3-methoxyoxolan-2-yl]-1,2,3,4-tetrahydropyrimidine-2,4-dione
- SMILES
- CO[C@@H]1[C@H](OP(=O)(OC[C@H]2O[C@H](C[C@@H]2O)N2C=NC3=C2N=CN=C3N)SCOC(=O)OC(C)C)[C@@H](CO)O[C@H]1N1C=CC(=O)NC1=O
References
- General References
- Not Available
- External Links
- ChemSpider
- 24667419
- ChEMBL
- CHEMBL1076930
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Viral Hepatitis B / Virus Hepatitis 1 2 Terminated Treatment Chronic Hepatitis B Infection 1 2 Terminated Treatment Chronic Hepatitis B Infection / HBV / Viral Hepatitis B 3 1 Completed Treatment Drug Interaction Potentiation 1 1 Completed Treatment Hepatitis C Infections 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 1.68 mg/mL ALOGPS logP -0.3 ALOGPS logP -0.27 Chemaxon logS -2.6 ALOGPS pKa (Strongest Acidic) 9.7 Chemaxon pKa (Strongest Basic) 3.96 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 14 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 258.24 Å2 Chemaxon Rotatable Bond Count 15 Chemaxon Refractivity 158.25 m3·mol-1 Chemaxon Polarizability 65.94 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at May 20, 2019 14:46 / Updated at February 21, 2021 18:55